Disialoganglioside GD2 as a therapeutic target for human diseases

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Conjugate 100%
• Carcinogenesis 50%
• Diseases 50%
• Metastasis 50%
• Antibody 50%
• Neoplasm 50%
• Small Cell Lung Cancer 50%
• Melanoma 50%
• Vaccine 50%
• Neuroblastoma 50%
• Solid Malignant Neoplasm 50%
• Vertebrate 50%
• Ganglioside 50%
• Glioma 50%
• Retinoblastoma 50%
• Invertebrate 50%
• Osteosarcoma 50%
• Bispecific Antibody 50%
• Fibrosarcoma 50%
• Rhabdomyosarcoma 50%
• Liposarcoma 50%
• Leiomyosarcoma 50%
• Ganglioside GD2 50%
• Chimeric Antigen Receptor 50%